Home   About the Journal  Editorial Board  Online Journal   Publishing Ethics   Contact Us  Chinese Version
You are here:Home => Online Journal => Vol.36 No.11 => Reviews =>
From nonalcoholic fatty liver disease to metabolic fatty liver disease: An analysis based on disease heterogeneity
文章发布日期:2020年10月22日  来源:  作者:冯巩,严琴琴,贺娜,等  点击次数:147次  下载次数:44次
Adjust font size:Small regular big

【Abstract】:Nonalcoholic fatty liver disease (NAFLD) has become the most important chronic liver disease in the world, but there is still no approved drug for clinical practice. Due to the heterogeneity of NAFLD itself, although drug therapy is being developed, the response rate seems to remain low. In order to meet the needs of clinical trial design and provide accurate information for drug developers, relevant scholars have proposed to change the name of NAFLD to metabolic associated fatty liver disease This article summarizes the origin of NAFLD heterogeneity and the background of NAFLD renaming, so as to provide new ideas for accelerating the development of new therapies.
【Key words】:non-alcoholic fatty liver disease; metabolic fatty liver disease; heterogeneity

Mail address: Editorial Office of Journal of Clinical Hepatology, 519 Dongminzhu Street, Changchun, Jilin, China Postal code: 130061 Tel:+86-431-88782542/3542
Journal of Clinical Hepatology Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号